Eisai's ambition to develop an integrated care system for people with dementia has taken another step forward with a decision to take control of EcoNaviSta, a specialist in software used to provide patient monitoring.

卫材开发痴呆症患者综合护理系统的雄心又向前迈进了一步，决定掌控专门从事用于患者监测的软件的EcoNaviSta。

The Japanese pharma company – currently in the process of rolling out new amyloid-targeting Alzheimer's therapy Leqembi (lecanemab) worldwide – has launched a JPY 2,190-per-share tender offer for EcoNaviSta's shares on the Tokyo Stock Exchange, less than a year after partnering with the company.

这家日本制药公司目前正在全球范围内推出新的针对淀粉样蛋白的阿尔茨海默病疗法Leqembi（lecanemab），该公司在与EcoNaviSta合作不到一年后，于东京证券交易所发起了每股2,190日元的要约收购。

Shares in EcoNaviSta closed up two-thirds at JPY 2,116 today, and the total purchase price for the company is expected to be approximately JPY 16 billion ($107 million).

EcoNaviSta的股票今日收盘上涨了三分之二，达到2,116日元，该公司的总收购价格预计约为160亿日元（1.07亿美元）。

EcoNaviSta has developed a software-as-a-service (SaaS) platform for home monitoring systems used in nursing care and has been working with Eisai to harness the technology to pick up changes in cognitive function among residents in care home facilities.

EcoNaviSta 开发了一种用于护理领域家庭监控系统的软件即服务（SaaS）平台，并一直与卫材合作，利用该技术来监测养老设施居民认知功能的变化。

The care home setting is important in Japan as, among the country's rapidly ageing population, a large number of the elderly choose to move into non-assisted living facilities – i.e. those without nursing support – or condominium developments aimed at seniors.

在日本，养老院的环境非常重要，因为在该国迅速老龄化的人口中，许多老年人选择搬入非辅助生活设施（即没有护理支持的设施）或专为老年人设计的公寓楼。

The collaboration has looked at combining Eisai's

该合作着眼于结合卫材的

NouKNOW

诺知

smart device-based app – which allows people to self-assess their cognitive performance and spot declines that may signal the onset of dementia – alongside EcoNaviSta's Life Rhythm Navi, which generates a health status rating from sleep and lifestyle data, and a patented dementia prediction software platform..

基于智能设备的应用程序——允许人们自我评估认知能力，并发现可能预示痴呆症开始的衰退迹象——与EcoNaviSta的Life Rhythm Navi相结合，后者根据睡眠和生活方式数据生成健康状态评分，以及一个获得专利的痴呆症预测软件平台。

In 2023, Eisai launched a dedicated subsidiary company called

2023年，卫材成立了专门的子公司，名为

Theoria Technologies

理论技术

that is developing a 'digital ecosystem' to support people with dementia, built around NouKNOW, and EcoNaviSta's software will add to that effort as a 'core solution,' said the company. It has also partnered with Tokyo-based Lifenet Insurance Co to develop a series of insurance products specifically for people with dementia and other ageing-related diseases..

该公司表示，正在开发一个围绕NouKNOW构建的“数字生态系统”以支持痴呆症患者，而EcoNaviSta的软件将作为“核心解决方案”为这一努力做出贡献。该公司还与总部位于东京的Lifenet保险公司合作，开发一系列专门为痴呆症患者和其他与衰老相关疾病设计的保险产品。

'Eisai believes that it will be possible to create pathways that will lead to the encouragement of visits to medical institutions by visualising risks using EcoNaviSta's dementia prediction AI and...NouKNOW for users of Life Rhythm Navi,' said the drugmaker.

“卫材认为，通过使用EcoNaviSta的痴呆症预测AI和Life Rhythm Navi用户的NouKNOW来可视化风险，将能够创建鼓励人们前往医疗机构的途径。”

The hope is that will in turn lead to 'early examinations, diagnosis, and treatment among sufferers with undiagnosed [mild cognitive impairment] and dementia,' it added. At the same time, Eisai hopes to generate real-world data from the platform that can be used to develop new services in dementia and other disorders such as insomnia and epilepsy..

它补充说，希望这将“促使未确诊的[轻度认知障碍]和痴呆症患者进行早期检查、诊断和治疗”。同时，卫材希望从该平台生成真实世界的数据，用于开发痴呆症及其他疾病（如失眠和癫痫）的新服务。